The pharmaceutical world is seeing a significant shift in diabetes treatment with the arrival of GLP-1 transdermal devices. These systems offer a possibly more user-friendly alternative to shots of GLP-1 drugs, minimizing the frequency of daily needle pokes. The innovation administers the drug directly through the skin, arguably improving patient a